Hence, in multiple sclerosis (MS) patients, the α4-inhibitor natalizumab reduced the number of CD4+ cells in CSF (93) as well as relapse frequency (94), and in assays that use immune cells from MS patients, natalizumab blocked the transmigration across layers mimicking BBB (93). Here, CD4 is linked to myeloid sarcoma.